EP0736035A4 - Procedes et composes de preciblage - Google Patents

Procedes et composes de preciblage

Info

Publication number
EP0736035A4
EP0736035A4 EP95910066A EP95910066A EP0736035A4 EP 0736035 A4 EP0736035 A4 EP 0736035A4 EP 95910066 A EP95910066 A EP 95910066A EP 95910066 A EP95910066 A EP 95910066A EP 0736035 A4 EP0736035 A4 EP 0736035A4
Authority
EP
European Patent Office
Prior art keywords
compounds
pretargeting methods
pretargeting
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95910066A
Other languages
German (de)
English (en)
Other versions
EP0736035A1 (fr
Inventor
Eric K Yau
Louis J Theodore
Linda M Gustavson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of EP0736035A1 publication Critical patent/EP0736035A1/fr
Publication of EP0736035A4 publication Critical patent/EP0736035A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP95910066A 1993-11-22 1994-11-22 Procedes et composes de preciblage Withdrawn EP0736035A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/156,565 US6022966A (en) 1993-11-22 1993-11-22 Pretargeting methods and compounds
PCT/US1994/013485 WO1995015335A2 (fr) 1993-11-22 1994-11-22 Procedes et composes de preciblage
US156565 1999-09-28

Publications (2)

Publication Number Publication Date
EP0736035A1 EP0736035A1 (fr) 1996-10-09
EP0736035A4 true EP0736035A4 (fr) 1999-09-01

Family

ID=22560099

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95910066A Withdrawn EP0736035A4 (fr) 1993-11-22 1994-11-22 Procedes et composes de preciblage

Country Status (5)

Country Link
US (1) US6022966A (fr)
EP (1) EP0736035A4 (fr)
JP (1) JPH09505831A (fr)
CA (1) CA2177136A1 (fr)
WO (1) WO1995015335A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358490B2 (en) * 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US5911969A (en) * 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
CA2257357C (fr) * 1996-06-07 2010-04-13 Neorx Corporation Anticorps humanises a glycosylation modifiee
KR100430061B1 (ko) * 2000-03-21 2004-05-03 재단법인 아산사회복지재단 글루코스 유도체에 방사성 동위원소가 표지된 착화합물 및이를 생산하기 위한 조성물이 포함된 키트
US6825032B2 (en) * 2001-05-14 2004-11-30 Sigma-Aldrich Co. High capacity assay platforms
JP4801348B2 (ja) 2002-05-06 2011-10-26 エンドサイト，インコーポレイテッド ビタミンを標的とした造影剤
DE60326465D1 (de) * 2002-09-03 2009-04-16 Univ Zuerich Herstellung von m(co)3-komplexen durch festphasentechniken durch metal-unterstützte trennung vom festen träger
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
US20090285771A1 (en) * 2004-10-04 2009-11-19 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
WO2007067597A2 (fr) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Procedes et compositions d'apport sans aiguille de partenaires de liaison
WO2007067596A2 (fr) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Procedes et compositions servant a l'apport, sans aiguille, d'anticorps
WO2007109110A2 (fr) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Procédés permettant d'augmenter la taille d'animaux au moyen de constructions d'apport sans aiguille
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
CA2699394C (fr) 2007-09-17 2020-03-24 The Regents Of The University Of California Anticorps monoclonaux humains internalisants ciblant des cellules du cancer de la prostate in situ
CN105388287A (zh) 2011-03-11 2016-03-09 内布拉斯加大学董事委员会 冠状动脉疾病的生物标志物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
BR112015008365A2 (pt) 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
US9044505B2 (en) * 2012-12-13 2015-06-02 Kumar Ranjan Bhushan Multimeric biotinidase resistant multimodality probes
WO2017030893A1 (fr) 2015-08-14 2017-02-23 Endocyte, Inc. Méthode d'imagerie utilisant un composé chélateur
SI3383920T1 (sl) 2015-11-30 2024-06-28 The Regents Of The University Of California Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
WO2018089829A1 (fr) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cellules effectrices spécifiques de cd46 et leurs utilisations
ES3057687T3 (en) * 2017-07-06 2026-03-04 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
EP4192511A1 (fr) 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Immunoconjugués ciblant cd46 et procédés d'utilisation associés

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031303A2 (fr) * 1979-12-21 1981-07-01 Ciba-Geigy Ag Cyclooctapeptides et leurs préparations pharmaceutiques, procédé pour leur préparation et leur application
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
EP0519554A1 (fr) * 1991-06-19 1992-12-23 Merck & Co. Inc. Conjugués de la protéine classe II de la membrane éxtérieure de neisseria méningitidis et de peptides associés à HIV-1
WO1993025240A2 (fr) * 1992-06-09 1993-12-23 Neorx Corporation Procedes et composes de preciblage
WO1994011398A1 (fr) * 1992-11-18 1994-05-26 The Du Pont Merck Pharmaceutical Company COMPOSES CYCLIQUES LIES PAR UN NOYAU HETEROCYCLIQUE UTILISES EN TANT QU'INHIBITEURS DE LA GLYCOPROTEINE IIb/IIIa PLAQUETTAIRE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0015334B1 (fr) * 1977-08-04 1982-05-19 J.B. Tillott Limited Préparations carminatives contenant l'huile de menthe ou ses composés actifs
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
AU621585B2 (en) * 1988-02-03 1992-03-19 Hybritech Incorporated Improvements in or relating to modified haptens useful as imaging and therapeutic agents
JPH0720989B2 (ja) * 1988-05-25 1995-03-08 アメリカ合衆国 大環状キレート化合物の抱合体と診断的テスト方法
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
SE465155B (sv) * 1989-12-19 1991-08-05 Exploaterings Ab Tbf Metallkelatbildande hydrofil polymer foer adsorption etc samt ett saett foer framstaellning av polymeren
JP2776953B2 (ja) * 1990-04-10 1998-07-16 日本メジフィジックス株式会社 多官能性金属キレート化合物とその用途
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5326778A (en) * 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031303A2 (fr) * 1979-12-21 1981-07-01 Ciba-Geigy Ag Cyclooctapeptides et leurs préparations pharmaceutiques, procédé pour leur préparation et leur application
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
EP0519554A1 (fr) * 1991-06-19 1992-12-23 Merck & Co. Inc. Conjugués de la protéine classe II de la membrane éxtérieure de neisseria méningitidis et de peptides associés à HIV-1
WO1993025240A2 (fr) * 1992-06-09 1993-12-23 Neorx Corporation Procedes et composes de preciblage
WO1994011398A1 (fr) * 1992-11-18 1994-05-26 The Du Pont Merck Pharmaceutical Company COMPOSES CYCLIQUES LIES PAR UN NOYAU HETEROCYCLIQUE UTILISES EN TANT QU'INHIBITEURS DE LA GLYCOPROTEINE IIb/IIIa PLAQUETTAIRE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHMIDT, ULRICH ET AL: "Synthesis of peptide alkaloids. 5. New method for synthesis of ansa peptides. Amino acids and peptides. 34", J. ORG. CHEM. (1982), 47(17), 3261-4 CODEN: JOCEAH;ISSN: 0022-3263, 1982, XP002106953 *

Also Published As

Publication number Publication date
EP0736035A1 (fr) 1996-10-09
US6022966A (en) 2000-02-08
JPH09505831A (ja) 1997-06-10
WO1995015335A2 (fr) 1995-06-08
CA2177136A1 (fr) 1995-06-08
WO1995015335A3 (fr) 1995-07-20

Similar Documents

Publication Publication Date Title
EP0736035A4 (fr) Procedes et composes de preciblage
GB9422158D0 (en) N-acylindoles and related compounds
DE69400639D1 (en) Rehydratationsgetraenk
DE69401926D1 (en) Hydroxamsäurederivate
DE69406448D1 (en) Luftreinigungsgerät
GB9419218D0 (en) Methods
ZA947833B (en) 4-Arylamino-benzopyran and related compounds
EP0734398A4 (fr) Composes et procedes
DE69405713D1 (en) Carbonylierungsverfahren
DE59407177D1 (en) 2-fluorcycloyhexen-derivate
DE59409705D1 (en) 3-methoxy-2-phenyl-acrylsäuremethylester
DE69408437D1 (en) Oxychlorierungsverfahren
DE59408644D1 (en) Jacquardmaschine
DE69407946D1 (en) Oxychlorierungskatalysator
DE59408733D1 (en) Metallhalogenidentladungslampe
AU122479S (en) Label-printer
DE59410065D1 (en) 3-methoxy-2-phenyl-acrylsäuremethylester
DE69410761D1 (en) Polyacetalharzzusammensetzung
DE69412128D1 (en) Kühlcontainer
GB9315306D0 (en) Methods
GB9315340D0 (en) Methods
GB9315351D0 (en) Methods
DE59407310D1 (en) Phenylazotriazolopyridinfarbstoffe
DE69327259D1 (en) Signalmetrikabschätzer
GB9308780D0 (en) Methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990720

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20011011

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEORX CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040225